findmyKOL
Clinical trialNCT02742103CompletedPhase 2Interventional

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

SponsorCSL BehringEnrollment83Acute Myocardial InfarctionModerate Renal Impairment
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a phase 2, multicenter, double-blind, randomized, placebo controlled, parallel-group study to investigate the renal safety and tolerability of multiple dose intravenous (IV) administration of CSL112 compared with placebo in subjects with moderate renal impairment (RI) and acute myocardial infarction (AMI).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

31 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Germany
  • Study Site 17001

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Study Site 17014

    Frankfurt am Main, Hesse, Germany

  • Study Site 17003

    Berlin, Germany

  • Study Site 17005

    Berlin, Germany

  • Study Site 17009

    Berlin, Germany

  • Study Site 17006

    Hamburg, Germany

Hungary
  • Study Site 18001

    Budapest, Hungary

  • Study Site 18005

    Budapest, Hungary

  • Study Site 18007

    Nyíregyháza, Hungary

  • Study Site 18003

    Pécs, Hungary

  • Study Site 18009

    Szeged, Hungary

Israel
  • Study Site 19005

    Haifa, Israel

  • Study Site 19002

    Nahariya, Israel

  • Study Site 19008

    Safed, Israel

Netherlands
  • Study Site 21001

    Alkmaar, Netherlands

  • Study Site 21006

    Amsterdam, Netherlands

  • Study Site 21017

    Amsterfoort, Netherlands

  • Study Site 21008

    Nijmegen, Netherlands

United States
  • Study Site 16101

    Birmingham, Alabama, United States

  • Study Site 16078

    Huntsville, Alabama, United States

  • Study Site 16168

    Concord, California, United States

  • Study Site 16130

    Littleton, Colorado, United States

  • Study Site 16135

    Danbury, Connecticut, United States

  • Study Site 16003

    Jacksonville, Florida, United States

  • Study Site 16112

    Boise, Idaho, United States

  • Study Site 16208

    Alexandria, Louisiana, United States

  • Study Site 16061

    Petoskey, Michigan, United States

  • Study Site 16056

    Durham, North Carolina, United States

  • Study Site 16014

    High Point, North Carolina, United States

  • Study Site 16018

    Rapid City, South Dakota, United States

  • Study Site 16241

    Wichita Falls, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CSL_112
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 2016
Primary completion
30 Jun 2017
Completion
30 Jun 2017
Last update posted
11 Jun 2020
Registered enrollment
83
Registry id
NCT02742103

Cross-registrations

EU-CTR / CTIS (EudraCT)2015-003017-26
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.